Imperial College London
Portrait Picture

ProfessorShiraneeSriskandan

Faculty of Medicine, Department of Infectious Disease

Professor of Infectious Diseases
 
 
 
//

Contact

 

s.sriskandan

 
 
//

Assistant

 

Ms Teyanna Gaeta +44 (0)20 3313 1943

 
//

Location

 

8N21ACWBCommonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Jones:2018:10.1016/j.vaccine.2018.05.056,
author = {Jones, S and Moreland, NJ and Zancolli, M and Raynes, J and Loh, JMS and Smeesters, PR and Sriskandan, S and Carapetis, JR and Fraser, JD and Goldblatt, D},
doi = {10.1016/j.vaccine.2018.05.056},
journal = {Vaccine},
pages = {3756--3763},
title = {Development of an opsonophagocytic killing assay for group a streptococcus},
url = {http://dx.doi.org/10.1016/j.vaccine.2018.05.056},
volume = {36},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Group A Streptococcus (GAS) or Streptococcus pyogenes is responsible for an estimated 500,000 deaths worldwide each year. Protection against GAS infection is thought to be mediated by phagocytosis, enhanced by bacteria-specific antibody. There are no licenced GAS vaccines, despite many promising candidates in preclinical and early stage clinical development, the most advanced of which are based on the GAS M-protein. Vaccine progress has been hindered, in part, by the lack of a standardised functional assay suitable for vaccine evaluation. Current assays, developed over 50 years ago, rely on non-immune human whole blood as a source of neutrophils and complement. Variations in complement and neutrophil activity between donors result in variable data that is difficult to interpret. We have developed an opsonophagocytic killing assay (OPKA) for GAS that utilises dimethylformamide (DMF)-differentiated human promyelocytic leukemia cells (HL-60) as a source of neutrophils and baby rabbit complement, thus removing the major sources of variation in current assays. We have standardised the OPKA for several clinically relevant GAS strain types (emm1, emm6 and emm12) and have shown antibody-specific killing for each emm-type using M-protein specific rabbit antisera. Specificity was demonstrated by pre-incubation of the antisera with homologous M-protein antigens that blocked antibody-specific killing. Additional qualifications of the GAS OPKA, including the assessment of the accuracy, precision, linearity and the lower limit of quantification, were also performed. This GAS OPKA assay has the potential to provide a robust and reproducible platform to accelerate GAS vaccine development.
AU  - Jones,S
AU  - Moreland,NJ
AU  - Zancolli,M
AU  - Raynes,J
AU  - Loh,JMS
AU  - Smeesters,PR
AU  - Sriskandan,S
AU  - Carapetis,JR
AU  - Fraser,JD
AU  - Goldblatt,D
DO  - 10.1016/j.vaccine.2018.05.056
EP  - 3763
PY  - 2018///
SN  - 0264-410X
SP  - 3756
TI  - Development of an opsonophagocytic killing assay for group a streptococcus
T2  - Vaccine
UR  - http://dx.doi.org/10.1016/j.vaccine.2018.05.056
UR  - https://www.ncbi.nlm.nih.gov/pubmed/29776751
UR  - http://hdl.handle.net/10044/1/60041
VL  - 36
ER  -
Download